When consolidating de novo oligometastatic NSCLC with initial hilar nodal involvement, would you still include the hilum if that disease completely responded to induction chemotherapy?
Would you get repeat invasive mediastinal staging to confirm response?
Answer from: Radiation Oncologist at Academic Institution
If the patient had oligo-met before induction chemotherapy, I would consider to TX all previously involved sites. However, if the patient has oligo-met after induction chemotherapy but had poly-met before chemotherapy, I would only TX active residual disease.